| P50 | author | Michael Kaabak | Q50227379 |
| | Alan K. Zokoev | Q84247319 |
| | Valery A Sandrikov | Q86205551 |
| | Valery A Sandrikov | Q86205552 |
| P2093 | author name string | Alexey A Maschan | |
| | Dmitry V Samsonov | |
| | Nadezda N Babenko | |
| P2860 | cites work | Differential CD52 expression by distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantation | Q28209687 |
| | Campath-1H monoclonal antibody therapy | Q34086162 |
| | H-Y antibody development associates with acute rejection in female patients with male kidney transplants | Q34147590 |
| | Antilymphoid antibody preconditioning and tacrolimus monotherapy for pediatric kidney transplantation | Q34201121 |
| | Alemtuzumab induction in renal transplantation | Q34660489 |
| | Dendritic cells: tools and targets for transplant tolerance. | Q36319502 |
| | Some observations on prope tolerance. | Q37888418 |
| | Banff 07 classification of renal allograft pathology: updates and future directions | Q40121163 |
| | Kidney transplantation with minimized maintenance: alemtuzumab induction with tacrolimus monotherapy--an open label, randomized trial | Q42612762 |
| | Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). | Q44514934 |
| | The natural history of chronic allograft nephropathy | Q44688416 |
| | Prevalence and subtypes of BK virus in pediatric renal transplant recipients in Russia. | Q45359954 |
| | Two hundred living donor kidney transplantations under alemtuzumab induction and tacrolimus monotherapy: 3-year follow-up. | Q46177056 |
| | Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation--efficacy and safety at five years. | Q46485560 |
| | Costimulation blockade with belatacept in renal transplantation | Q46569880 |
| | Alemtuzumab (Campath-1H) induction therapy and dendritic cells: Impact on peripheral dendritic cell repertoire in renal allograft recipients. | Q53585469 |
| | Prediction of cyclosporine area under the curve using a three-point sampling strategy after Neoral administration | Q57704087 |
| | The Banff 97 working classification of renal allograft pathology | Q59314413 |
| | Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients | Q61651688 |
| | REMISSION INDUCTION IN NON-HODGKIN LYMPHOMA WITH RESHAPED HUMAN MONOCLONAL ANTIBODY CAMPATH-1H | Q61651778 |
| | Calcineurin inhibitor withdrawal in stable kidney transplant patients decreases the donor-specific cytotoxic T lymphocyte precursor frequency | Q81546062 |
| | Campath-1H use in pediatric renal transplantation | Q81737693 |
| | Discontinuation of calcineurin inhibitors treatment allows the development of FOXP3+ regulatory T-cells in patients after kidney transplantation | Q84574131 |
| | Pediatric living donor kidney transplantation under alemtuzumab pretreatment and tacrolimus monotherapy: 4-year experience | Q95819040 |
| P433 | issue | 2 | |
| P304 | page(s) | 168-178 | |
| P577 | publication date | 2013-03-01 | |
| P1433 | published in | Pediatric Transplantation | Q7159217 |
| P1476 | title | Alemtuzumab induction in pediatric kidney transplantation | |
| P478 | volume | 17 | |